[Comment] Confirming cross-protection of bivalent HPV vaccine

Prophylactic human papillomavirus (HPV) vaccines have exceeded expectations in preventing infection with oncogenic HPV, the underlying cause of cervical cancer. Both the bivalent HPV vaccine and quadrivalent HPV vaccine contain virus-like particles that induce high-level antibody responses to HPV types 16 and 18, the two most oncogenic HPV types, which are responsible for 71% of cervical cancer cases globally.1 In the 11 years since their first licensure, the vaccines have been distributed globally in over 270 million doses and are demonstrably safe in population usage.

Source: The Lancet Infectious Diseases - September 28, 2017 Category: Infectious Diseases Authors: Julia M L Brotherton Tags: Comment Source Type: research